Kv1.3 Therapeutics is a clinical stage biopharmaceutical company focused on advancing new treatment options for rare diseases. Our initial focus is on the use of our novel Kv1.3 inhibitor for the treatment of inclusion body myositis a rare progressive disease of the muscle. Our portfolio is based on a novel platform of compounds which are potent and highly specific Kv1.3 inhibitors. We are a privately-owned virtual Seattle based company that leverages the scientific backbone Kineta Inc, a translational development biotech company. We are lead by a team of experienced scientists and industry executives dedicated to develop safe and effective therapies to those patients.